News Center

FDANews; August 30, 2021 – Molecular diagnostics company CellMax Life’s FirstSight pre-cancer and cancer detection blood test has received the FDA’s Breakthrough Device designation....

GenomeWeb; August 27, 2021 – CellMax Life said this week that its FirstSight colorectal precancer and cancer detection blood test has received Breakthrough Device Designation from the US Food an...

Aug. 26, 2021 – The FirstSight blood test is a liquid biopsy, which will help measure colorectal neoplasia associated epithelial cells and DNA markers in human blood...

Aug. 25, 2021 – CellMax Life, a molecular diagnostics company, announced today that its FirstSight™ pre-cancer and cancer detection blood test has received Breakthrough Device Designation from t...

Mar 23, 2021 – CellMax Life closes Series C financing to accelerate development and regulatory approvals of FirstSight...

January 26, 2021 – A blood test for early detection of colorectal adenomas and cancer shows promise for improving survival and prevention of colorectal cancer (CRC) by enabling the stratificatio...

January 15, 2021 – A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results pr...

MedScape | June 01, 2020 A blood test detected 11 of 11 cases of colorectal cancer in a study involving 354 patients, and also spotted a majority of cases — 40 out of 53 — in which participants had ad...

Data now available, via 2020 ASCO Virtual Scientific Program, demonstrates early detection of colorectal neoplasia and significant association with size and number of polyps...

OncLive | May 08, 2020 The multimodal FirstSightCRC blood test demonstrated higher sensitivity and specificity than standard screening protocols in detecting advanced adenomas and colorectal cancer (C...

NEW YORK (GenomeWeb) – Researchers shared new data this week from a study of the colorectal cancer screening test being developed by CellMax life, providing the first prospective sensitivity and speci...

MedPage Today | May 7, 2020 Testing blood for three distinct colorectal cancer (CRC) markers showed perfect sensitivity and 90% specificity for detecting malignancy in a preliminary study, researchers...

Healio Gastroenterology | May 6, 2020 A novel, blood-based assay improved the detection of advanced and non-advanced adenomas by analyzing cell-free DNA and circulating gastrointestinal epithelial cel...

Becker’s Hospital Review | May 04, 2020 CellMax Life released results from its U.S. study of the FirstSight blood test that revealed the test detected colorectal cancer with 100 percent sensitiv...

FirstSight test achieved 90% specificity, with sensitivity of 100% and 76% for detection of colorectal cancer and advanced adenomas, respectively. Data is now available via Digestive Disease Week® (DD...

BIOCENTURY | JAN 18, 2018 CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. Th...

HealthNewsDigest | Jan 20, 2019 According to the American Society for Gastrointestinal Endoscopy, colorectal cancer (aka colon cancer) is the second leading cause of cancer-related deaths in the Unite...

MD+DI | 01/09/2019 – CellMax Life has developed a blood test that it says can identify precancerous adenomas with similar accuracy as colonoscopy, which may facilitate better compliance with scr...

NEW YORK (GenomeWeb) – JAN 02, 2019 Sunnyvale, California-based CellMax Life said today that it has partnered with Taiwan-based Medigen Biotech as part of the firm’s cell therapy clinical trials. Medi...

CellMax Life said today its CMx™ circulating tumor cell (CTC) platform and liquid biopsy panel will be used by Medigen Biotech in upcoming clinical trials of its cell therapy candidates for cancers, w...